Can-Fite BioPharma Ltd. (CANF), Friday announced that the Brazilian Patent Office has granted patent entitled Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.
Following this, the granted patent provides intellectual-property protection in Brazil for the use of Can-Fites proprietary A3AR agonists in the treatment of sexual dysfunction.
The patent reflects the company's broader clinical and preclinical programs, which is expected to help create future partnering or commercialization opportunities in Latin America.
In the pre-market hours, CANF is trading at $0.24, down 1.94 percent on the New York Stock Exchange American.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.